News und Analysen

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences:

• 
  Annaliesa Anderson, SVP & Head

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:

• 
  Jereme Sylvain, Executive Vice President and

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023.

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for ABRYSVO^™, the company’s bivalent respiratory syncytial virus (RSV) prefusion F

Agilent Technologies Inc. (NYSE: A) today announced the issuing of a companion diagnostic (CDx) Class C IVDR certification for PD-L1 IHC 22C3 pharmDx, Code SK006. This CDx assay has previously been

Leading health and well-being company Humana Inc. (NYSE: HUM), and kidney care management company Interwell Health, have announced a new value-based care agreement in 13 states for most Humana

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F

Humana (NYSE: HUM) announced sixteen community-based organizations across the nation will receive grants totaling over $121,500. With millions of medical and specialty care members across the

For the third year in a row, Humana ranked No. 1 among health insurers for customer experience (CX) by Forrester*. Humana received the highest CX Index™ score among Health Insurers in Forrester’s

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the third quarter ended July 31, 2023, a decrease of 2.7% compared to the third quarter of 2022 and a decrease of

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to

Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed

Agilent Technologies Inc. (NYSE: A) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced a partnership with Greater Louisville Inc. (GLI) to help small business mental health

Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2023. The company narrowed its 2023 revenue guidance⁽⁴⁾ range to $67 to $70 billion, while maintaining its outlook for

Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company’s work supporting customers with their sustainability initiatives while advancing its own internal

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023.

Second Quarter 2023 Financial Highlights:

• 
  Revenue grew 25% versus the same

Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and